STAAR Surgical Co (STAA): רווח למניה בשנים עשר החודשים האחרונים

STAAR Surgical Company (STAA) leverages its global leadership in the niche eye implant segment, expanding successfully across Asia and the US. Personnel stability ensures R&D prestige and rigorous quality control. This chart of net profit per share over the last 12 months from the GURU.Markets base service confirms resilience, with the current level sitting around 0.00, highlighting the technological monopoly of ICL and the company's pricing power to dictate premium pricing.
פילוחים אנליטיים של חברת STAAR Surgical Company (STAA)

To minimize long-term capital risks, monitoring the dynamics of net income per common share over a rolling year is critically important. An analysis of the 12-month EPS trend confirms how the impeccable status of STAAR Surgical Company (STAA) in ophthalmology converts into real returns, allowing investors to assess the efficiency of profit management relative to the total volume of issuance.